2018-HCV Genotypes/Treatment

2018 HCV Genotypes and Treatment
Offered on this page is research updates with a focus on treating HCV according to genotype using FDA approved and investigational medicines. Information is extracted from news articles, peer-reviewed journals, as well as liver meetings/conferences, research manuscripts and interactive learning activities. 


Archives 
Research Articles
Current full-text articles covering every aspect of hepatitis C.


HCV Guidance Updates
The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America with the International Antiviral Society developed a living document with ever evolving guidelines to treat HCV

The following pages include guidance for management of  treatment-naive patients.
Genotype 1 
Genotype 2 
Genotype 3 
Genotype 4 
Genotype 5 or 6

The following pages include guidance for management of treatment-experienced patients.
Genotype 1 
Genotype 2 
Genotype 3 
Genotype 4 
Genotype 5 or 6 

Stay current with all guideline updates, "click here."

January 2018
Jan 23, 2018
This review is a collaboration between primary care and hepatology providers to explore all aspects of HCV management: acute versus chronic HCV infection, transmission and testing, and diagnosis and treatment. Specific medications for the treatment of HCV infection are considered, and patient and medication factors including genotype, liver disease status, and comorbidities affecting medication choice are discussed.

Chronic kidney disease stage G3 correlates with lower SVR rate
Genotype 2
Sovaldi with ribavirin was safe and effective among a cohort of Japanese patients with hepatitis C genotype 2. However, Chronic Kidney Disease, especially stage G3, correlated significantly with a lower rate of SVR.

In case you missed it
The Effect of Shorter Treatment Regimens for Hepatitis C on Population Health and Under Fixed Budgets.
Direct acting antiviral hepatitis C virus (HCV) therapies are highly effective but costly. Wider adoption of an 8-week ledipasvir/sofosbuvir treatment regimen could result in significant savings, but may be less efficacious compared with a 12-week regimen. We evaluated outcomes under a constrained budget and cost-effectiveness of 8 vs 12 weeks of therapy in treatment-naïve, noncirrhotic, genotype 1 HCV-infected black and nonblack individuals and considered scenarios of IL28B and NS5A resistance testing to determine treatment duration in sensitivity analyses.

New Issue @ Healio
HCV Next - ‘Think Outside the Box’ to Finance HCV Elimination
New Pricing Marks Potential HCV Treatment Landscape Revolution

Jan 18
Editorial: direct-acting antivirals significantly improve quality of life in patients with HCV

Jan 11
Genotype 1, 4 & 3
How will data presented at AASLD 2017 on 8-week therapy have an impact on management of patients with HCV infection? Here’s my take.

Genotype 1
Viekirax safety, efficacy comparable in HCV with chronic kidney ...
Healio
The safety and efficacy of Viekirax was comparable between patients with hepatitis C genotype 1b and chronic kidney disease and those without chronic kidney disease, according to a recently published study. “The HCV infection rate in CKD patients is higher than that in the general population, and the anti-HCV ...

Jan 10
Genotype 1
Full Text
Viekira Pak - Effect of ombitasvir/paritaprevir/ritonavir + dasabuvir regimen on health-related quality of life for patients with hepatitis C
During active treatment period, small but statistically significant decrements in HRQoL outcomes were observed potentially driven by RBV, which were not sustained during the post treatment follow up period. Differences were observed by patient subgenotype, where HRQoL improvements were consistently higher for GT1b patients as compared to GT1a patients

Jan 6
Genotype 3
Full Text
In summary, SURVEYOR-II Part 3 enrolled and treated some of the most difficult-to-cure HCV patients: those with GT3 infection and prior treatment experience and/or cirrhosis. Overall, the fixed-dose combination of once-daily RBV-free G/P was well tolerated and demonstrated high SVR12 rates (≥95%) in treatment-naive patients with cirrhosis treated for 12 weeks and treatment-experienced patients with or without cirrhosis treated for 16 weeks. Therefore, G/P provides an efficacious and well-tolerated once-daily RBV-free treatment option for patients with HCV genotype 3 and prior treatment experience and/or cirrhosis.

In Case You Missed It
Genotype 1,2, and 3
Full Text
CMAJ - January 5, 2018 vol. 6 no. 1 E12-E18
Real-world treatment of hepatitis C with second-generation direct-acting antivirals: initial results from a multicentre Canadian retrospective cohort of diverse patients
High hepatitis C cure rates have been observed in registration trials with second-generation direct-acting antivirals. Real-world data also indicate high sustained viral response (SVR) rates. Our objective was to determine real-world SVR rates for patients infected with hepatitis C virus (HCV) who were treated with second-generation direct-acting antivirals in the first 18 months of their availability in Canada. *Click image to enlarge, view full text article online, here or download PDF

Sustained viral response status by genotype and treatment regimen


Jan 5
2018 Year in Review - Hepatitis Newsletters, Headlines & Updates
Welcome folks, for a recap of this year's HCV accomplishments check out the following newsletter, blog and journal updates.

Genotype 1 and 6
Abstract - Sofosbuvir-ledipasvir with or without ribavirin for chronic hepatitis C genotypes 1 and 6: real-world experience in Vietnam
There was no significant difference in demographic data and treatment outcomes between patients with genotype 1 versus 6. Adverse events were mild with all SOF-LDV regimens, but appeared to be more common with 24-week treatment groups.

Conclusions: SOF-LDV with or without RBV was highly effective and safe in Vietnamese patients with HCV genotype 1 and 6.

Jan 1
Genotype 6
HCV Genotype 6 Responds to 8-Week Oral Treatment
The successful treatment of hepatitis C virus genotype 6 (HCV-GT6) with a non-interferon-based fixed dose oral regimen of ledipasvir and sofosbuvir (LDV/SOF) bodes well for treating HCV in Southeast Asia, where newer pangenotypic agents are not available to treat this region's most prevalent genotype.

The Long Road To Safe and Effective HCV Drugs: A Tribute To The People Who Helped Us Get There
Before we look ahead to 2018, I thought we might look back. Why? So that we may never forget just how far we've come, and the people who helped us get there.

20th Anniversary Edition of HCV Advocate's Newsletter 
IN THIS ISSUE
Celebrating 20 Years
Honoring Twenty Years of Hepatitis C Advocacy
Top Ten Stories
A Year in the Life of a Trainer

Full Text
Viral kinetics analysis & virological characterization of treatment failures in a real-world cohort with chronic HCV treated with SOF & an NS5A inhibitor (DCV or LDV)
This real-world study confirms the excellent results of clinical trials with therapies based on a combination of SOF plus an NS5A inhibitor. It suggests that a personalized approach including baseline NS5A inhibitor resistance testing may inform treatment decisions in cirrhotic patients.
Full-text article shared by @HenryEChang via Twitter

____________________
Archives
2017
2016

No comments:

Post a Comment